Enanta Pharma (ENTA) Tops Q1 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2015
February 8, 2016 4:02 PM ESTConference Call and Webcast Today at 4:30 p.m. ET
Royalty revenue for paritaprevir containing regimens was $17.9 million $30 million milestone payment received from AbbVie for reimbursement approval in Japan for VIEKIRAX® Cash and marketable securities totaled $236.6 million at December 31, 2015WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal first... More
